University of NC at Chapel Hill
Welcome,         Profile    Billing    Logout  
 1 Trial 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sanders, Georgiana
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
Ponda, Punita
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Recruiting
1/2
192
Canada, US
Peanut SLIT-tablet, Placebo
ALK-Abelló A/S, Parexel
Peanut Allergy
01/26
02/26
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
Talbert, Jennifer
SILDI-SAFE, NCT04447989: Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

Active, not recruiting
2
120
US
Sildenafil, Revatio, Placebo, Dextrose 5%
Christoph Hornik, University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Bronchopulmonary Dysplasia of Newborn
12/24
01/25
NCT01286519: Pharmacokinetics of Off Label Pediatric Medications

Recruiting
N/A
400
US
University of North Carolina, Chapel Hill
Off Label Use of Medications in Pediatric Patients
12/35
12/35
Bear, David
SOSTOS, NCT05090371: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Recruiting
4
150
Canada, US
Ofatumumab, Disease modifying treatment (DMT)
Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
12/26
12/26
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
06/24
03/26
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Recruiting
3
2060
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
MISSION, NCT06071468: Registry of the Patient Experience for Carpal Tunnel Release

Recruiting
N/A
2000
US
UltraGuideCTR (Device) with Ultrasound Guided Carpal Tunnel Release (CTR-US), Endocscopic CTR, ECTR, Open CTR, OCTR
Sonex Health, Inc.
Carpal Tunnel Syndrome, CTS
12/27
12/27
Hornik, Christoph
GRACE-2, NCT05266001: GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

Terminated
3
141
US
GM-CSF, Placebo
Nationwide Children's Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
12/24
12/24
TRIPS, NCT05267821: Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Recruiting
2/3
500
US
Anakinra, Placebo
Nationwide Children's Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
05/27
08/27
SILDI-SAFE, NCT04447989: Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

Active, not recruiting
2
120
US
Sildenafil, Revatio, Placebo, Dextrose 5%
Christoph Hornik, University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Bronchopulmonary Dysplasia of Newborn
12/24
01/25
NCT06613477: PK/PD of Digoxin in Infants With SVHD

Recruiting
1/2
20
US
PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease, Lanoxin
Duke University, Medical University of South Carolina, Duke Clinical Research Institute, National Center for Child Health and Development (NICHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Single-ventricle, Infant Conditions, Infant, Newborn, Diseases, Infant, Premature, Diseases
12/25
12/25
OPTIC, NCT05055830: Opportunistic PK/PD Trial in Critically Ill Children

Recruiting
N/A
2000
US
The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care., Methadone, Caffeine, Acetaminophen, Milrinone
Duke University, Food and Drug Administration (FDA)
Cardiac Disease, Critically Ill, Children, Adult
09/25
09/26
YMH, NCT05589376: You and Me Healthy

Enrolling by invitation
N/A
20000
US
Duke University
COVID-19
12/27
12/27
Jackson, Wesley M
SILDI-SAFE, NCT04447989: Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

Active, not recruiting
2
120
US
Sildenafil, Revatio, Placebo, Dextrose 5%
Christoph Hornik, University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Bronchopulmonary Dysplasia of Newborn
12/24
01/25
NCT03913221: Caffeine for Hypoxic-Ischemic Encephalopathy

Active, not recruiting
1
17
US
Caffeine Citrate 5 mg/kg, Cafcit, Caffeine Citrate 10 mg/kg
University of North Carolina, Chapel Hill, Thrasher Research Fund
Hypoxic-Ischemic Encephalopathy
01/23
12/24
NCT06448780: Dose Optimization of Caffeine for HIE

Recruiting
1
16
US
Caffeine citrate 20 mg/kg, Cafcit, Caffeine citrate 30 mg/kg
University of North Carolina, Chapel Hill, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hypoxic-Ischemic Encephalopathy
12/26
11/28
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting
N/A
5000
Canada, US
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
09/26
09/27
Laughon, Matt
SILDI-SAFE, NCT04447989: Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

Active, not recruiting
2
120
US
Sildenafil, Revatio, Placebo, Dextrose 5%
Christoph Hornik, University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Bronchopulmonary Dysplasia of Newborn
12/24
01/25
Ciotti, John
SOSTOS, NCT05090371: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Recruiting
4
150
Canada, US
Ofatumumab, Disease modifying treatment (DMT)
Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
12/26
12/26
OPTIS, NCT05566769: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

Recruiting
N/A
103
Europe, US
NMOSDCopilot smartphone application
Ad scientiam
Neuromyelitis Optica
04/25
04/26
Noe, Amber
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25

Download Options